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Abstract
Background: Human immunodeficiency virus (HIV)-1 infection increases the burden of malaria by increasing
susceptibility to infection and decreasing the response to malarial treatment. HIV-1 has also been found to
suppress the immune system and predispose to severe forms of malaria in adults. There is still a paucity of data on
the association between HIV-1 infection and cerebral malaria in children. The aim of this study was to determine
whether HIV-1 infection is a risk factor for cerebral malaria in children.
Method: We conducted an unmatched case-control study, in which 100 children with cerebral malaria were
compared with 132 with uncomplicated malaria and 120 with no malaria. In stratified analyses we estimated odds
ratios (ORs) and 95% confidence intervals (CIs) adjusted for age.
Results: HIV-1 infection was present in 9% of children with cerebral malaria compared to 2.3% in uncomplicated
malaria (age-adjusted odds ratio (aOR) 5.94 (95% confidence interval (CI) 1.36-25.94, p = 0.012); and 2.5% in
children with no malaria (aOR 3.85 (95% CI0.99-14.93, p = 0.037). The age-adjusted odds of being HIV-positive
among children with cerebral malaria compared to the control groups (children with uncomplicated malaria and
no malaria) was 4.98 (95% CI 1.54-16.07), p-value = 0.003.
Conclusions: HIV-1 infection is associated with clinical presentation of cerebral malaria in children. Clinicians
should ensure that children diagnosed with HIV infection are initiated on cotrimoxazole prophylaxis as soon as the
diagnosis is made and caretakers counselled on the importance of adherence to the cotrimoxazole towards
reducing the risk of acquiring P.falciparum malaria and associated complications such as cerebral malaria. Other
malaria preventive measures such as use of insecticide-treated mosquito nets should also be emphasized during
counselling sessions.
Background
Malaria and Human immunodeficiency virus (HIV)-1
are two of the most common global health challenges
today and the two infections commonly overlap in dis-
tribution in most countries especially in sub-Saharan
Africa [1]. Studies have demonstrated interaction
between these two infections with the majority of stu-
dies conducted in adults [2-6]. HIV-1 infection has been
found to be associated with severe forms of malaria and
particularly cerebral malaria in adults but there is still a
paucity of information on the interaction between the
two infections in children [2,7,8].
HIV-1 infected adults have a greater percentage of
severe malaria episodes with more frequent hospitaliza-
tions compared to their uninfected counterparts and
are at a greater risk of cerebral malaria [2,3,7,9]. Infection
with HIV-1 leads to impaired immune response
to malaria through cellular immunosuppression resulting
in a higher likelihood of increased parasitaemia and
severe malarial infections. Multiple studies have indicated
an alteration in cytokine levels in those co-infected with
malaria and HIV [10-12].
Malaria-specific antibodies, the main target of protec-
tive malaria immunity seem to be little impaired in early
HIV infection but in advanced AIDS, evidence indicates
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any medium, provided the original work is properly cited.B-cell stimulation is diminished to some extent, result-
ing in decreased production of malaria antibodies
[10,13]. HIV infection has also been found to increase
the susceptibility to new malarial infections [3,9]. There
is evidence also showing strong correlation between
decreasing CD4+ cell counts and both the levels of para-
sitaemia and the patients’ clinical status [12,14]. HIV-
infected children with advanced immunosuppression
have more episodes of clinical malaria and higher para-
site densities compared to those children without
advanced immunosuppression [15]. In children, cerebral
malaria is the most severe neurological complication of
P. falciparum malaria infection and has a case fatality
ranging from 5 to 40% [16-19].
Whether HIV-1 infection increases the risk of cerebral
malaria in children is not known. We conducted this
study to determine whether HIV infection is a risk fac-
tor for cerebral malaria in children from Uganda.
Methods
We conducted a case-control study of children with cer-
ebral malaria recruited from Mulago hospital Paediatric
emergency unit. We also recruited 132 children with
uncomplicated malaria and 120 with no malaria as con-
trols from the paediatric out patients units. Cases
included children aged below 12 years with cerebral
malaria [defined as a clinical syndrome characterized by
coma: Blantyre Coma Scale(BCS) ≤ 2] for more than
30 minutes after termination of a seizure or correction
of hypoglycaemia, detection of asexual forms of Pf a l c i -
parum malaria parasites on peripheral blood smears,
and a normal cerebrospinal fluid (CSF) [20]. The para-
site density was determined after enrolment and
was therefore not considered in the inclusion criteria.
Severe anemia was not an inclusion criterion per se but
children with severe anemia, who had a history of con-
vulsions and were admitted with a BCS ≤ 2 (in coma),
with a relatively normal blood sugar (at least above
2.2 mmol/l), normal electrolytes and a normal CSF with
a positive blood smear for malaria parasites were taken
as having cerebral malaria. The control group with
uncomplicated malaria included children aged below
12 years, with fever and a positive malarial smear.
Uncomplicated malaria was defined as fever with a posi-
tive blood smear for malaria parasites but no features of
severe malaria which include convulsions, inability to
drink, vomiting, and drowsiness, and lethargy, loss of
consciousness, respiratory distress, or severe anaemia.
Axillary temperature was measured and fever was con-
sidered above 37.6°C. A temperature above 39.5°C was
considered hyperpyrexia. For the control group with no
malaria, we included children aged below 12 years, with
no symptoms of malaria such as fever, malaise or weak-
ness and a negative blood smear for malaria parasites.
Children who had asymptomatic parasitaemia (positive
blood smear with no fever) were excluded from the
control group these constituted 10% of 133 children
screened with no malaria.
All children recruited in this study were of unknown
HIV status at time of enrolment and therefore were not
on cotrimoxazole prophylaxis. We required 100 cerebral
malaria cases to determine the association between HIV
infection and cerebral malaria, in a case to control ratio
of 1:1, with a power of 80% and 95% confidence interval
according to Fleiss formula for case control studies [21].
We continued to enrol controls until all the required
cases of cerebral malaria were recruited
A questionnaire was used to collect information such as
the socioeconomic, demographic characteristics, clinical
history, and physical examination as well as laboratory
findings. We consecutively enrolled patients who fulfilled
the inclusion criteria for the three study groups until the
sample size was achieved. Cases and controls were
recruited at the same time. Patients were examined by a
qualified medical officer who documented all the findings.
A trained counsellor was available to do both pre- and
post-test counselling for HIV. Five millilitres of blood
were drawn from each child with cerebral malaria and
2-3 millilitres in children with uncomplicated malaria for a
malaria smear, P. falciparum parasite density, HIV serol-
ogy and CD4 cell count, blood glucose and serum electro-
lytes which were done in different laboratories. A finger
prick was done for children with no malaria for the blood
smear and rapid HIV test and a blood sample for CD4
count taken if the child was found to be HIV positive. The
HIV tests were rapid and the children who were HIV posi-
tive had blood sent for CD4 cell count immediately. These
were used to stage level of immunosuppression according
to the WHO guidelines [22]. No repeat CD4 test was car-
ried out after treatment. Serum electrolytes were assessed
on all children with cerebral malaria. A lumbar puncture
was performed on the children with suspected cerebral
malaria and a normal CSF described as a specimen with
a cell count of ≤5W B C s / m m
3 and a CSF protein of
≤40 mg/dl. Patients with cerebral malaria and those with
uncomplicated malaria received standard care according
to the Mulago Hospital Department of Paediatrics guide-
l i n e s .T h o s ew i t h o u tm a l a r i aw e r es e e nb yt h es u r g e o n s
who offered appropriate treatment for the surgical condi-
tion. HIV positive children were referred to the Paediatric
I n f e c t i o u sD i s e a s eC l i n i c( P I D C )w h e r et h e yw e r ee v a l u -
ated, managed and followed up. The number of asexual
parasites per 200 white blood cells (WBCs) was counted
and parasite densities computed by assuming a mean
WBC count of 8,000/litre (WHO) [23].
The primary objective of this study was to assess
HIV-1 as an independent risk factor for cerebral
malaria. The secondary objective was to determine the
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malaria and the correlation between the level of immu-
nosuppression (CD4+ T-cell count) and parasite density.
Statistical Analysis
Data was entered into EPI-DATA 3.1 software package
and analysed using the statistical program SPSS version
13 software packages. Categorical variables were sum-
marized as proportions while means and standard devia-
tion were used for normally distributed continuous
variables. Medians with corresponding inter-quartile
ranges were used for skewed data. The Chi- square test
was used to compare categorical variables between those
cerebral malaria and those without. Multivariate analysis
(logistic regression by backward method) was then used
to tease out whether HIV infection is independently
associated with clinical cerebral malaria.
Ethics and Consent
Informed consent to participate in the study was
obtained from the caretakers after explanation of the
study objectives and relevance, risks and benefits.
A separate consent for HIV testing was also obtained.
Laboratory results were available for patient manage-
ment. Approval was obtained from the Makerere Uni-
versity Faculty of Medicine, Research and Ethics
Committees, Mulago Hospital, and the Uganda National
Council of Science and Technology.
Results
The study was conducted from November 2006 to March
2007 during which 352 children were recruited. One hun-
dred had cerebral malaria (CM), 132 had uncomplicated
malaria (UM) and 120 had no malaria (NM). Thirty two
patients with suspected cerebral malaria were excluded, 28
of whom we could not do complete assessment and 4 had
incomplete data. Ten percent (13/133) of children with no
malaria were found with asymptomatic parasitaemia and
these were also excluded from the analysis Figure 1. Chil-
dren hospitalized with cerebral malaria were more likely
to be less than five years of age (81% vs 68% and 63%) and
not to use mosquito nets (54% vs 86% and 63% in the
uncomplicated malaria and no malaria arms respectively).
Of the 352 children enrolled, 3 (2 cases and 1 control) had
moderate to severe wasting (Table 1a).
Children with cerebral malaria also had median serum
sodium of 137.0 mmol/L (range 131-142 mmol/L). One
patient had severe hypoglycaemia at the time of enrol-
ment (blood sugar below 2.2 mmol/L). The median
blood sugar was 7.4 mmol/L (range 5.9-9.5 mmol/L).
Thirty eight percent of patients with CM had severe
anaemia (Hb < 5 g/dl). No microbiological culture or
virological tests were done on the CSF since the white
blood cell count was not raised.
Children with cerebral malaria who were also HIV
positive children were more likely to have had fever for
more than three days, been on treatment prior to this
admission, present with higher temperatures (>38°C)
and have a higher parasite density (Table 1b). HIV posi-
tive children with cerebral malaria were also more likely
to have a higher parasite density. The unadjusted odds
of having parasite density greater than 500,000/μlw i t h
cerebral malaria was 12.71 times higher in HIV positive
children (95% CI; 0.77-189.57) compared to those who
were HIV negative. The age-adjusted OR was 13.76
(95% CI; 1.24-153.11), p-value = 0.0051.
S i x t ys e v e n( 5 6 % )o ft h e1 2 0c o n t r o l sw i t hn om a l a r i a
recruited from SOPD had inguino-scrotal hernias, 26
(22%) presented with hydroceles, and the others had con-
genital anorectal malformations, umbilical hernias,
undescended testis, rectal prolapse and different types of
cysts. None of these controls required urgent interven-
tion but only an appointment for elective surgery. Ideally,
these controls (no malaria) would have been selected
from similar communities as the cases but this was not
the case due to limited funds for this. This could have
potentially caused bias in the HIV prevalence. The preva-
lence of HIV was 9% among children with cerebral
malaria compared to 2.3% and 2.5% in the uncomplicated
malaria and no malaria groups respectively.
There was an association between HIV infection and
clinical cerebral malaria, HIV infected children were
more likely to have cerebral malaria than the HIV nega-
tive ones, unadjusted OR = 4.05 (95%CI 1.24-14.19), p =
0.006 and age-adjusted odds ratio (aOR) was 4.98 (95%
CI 1.54-16.07) p = 0.003. Among children below the age
of 5 years, the HIV prevalence in cerebral malaria cases
was 8.6% (7 of 81) compared to 1.2% (2 out of 166)
among all controls. The odds of presenting with clinical
cerebral malaria below the age of five was higher among
children who were HIV positive compared to the HIV
negative counter parts OR = 7.76 (95% CI; 1.42-77.6);
p-value 0.003 (Table 2).
On comparing the children with cerebral malaria to
those with the no malaria, the age-adjusted odds of pre-
senting with cerebral malaria was 3.85 times higher
among HIV positive children compared to HIV negative
ones, (95% CI = 0.99-14.93) p = 0.037. The aOR was
5.94 (95% CI 1.36-25.94) when comparing children with
cerebral malaria to children with uncomplicated malaria,
p-value 0.012 (Table 3). Table 4 shows a summary of
the age-adjusted odds ratios comparing the cases to the
control groups
The CD4 lymphocyte percentage and absolute counts
were used to determine the stage of HIV immunosup-
pression. Twenty percent HIV-positive children had
their stage of immune suppression by CD4 count cor-
responding to their WHO clinical stage. Fifty five
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malaria were not clinically immunosuppressed or just
h a dm i l di m m u n o s u p p r e s s i o nc o m p a r e dt o1 6 . 7 %o f
HIV positive children with uncomplicated or no
malaria. Children with cerebral malaria were more
likely to have mild to moderate immunosuppression
than were children without cerebral malaria (age-
adjusted OR = 3.33 (95%CI 0.25-45.11); p-value =
0.336). However, the numbers of HIV positive children
in this sample was very small.
Discussion
Our results are in agreement with studies conducted in
Kwazulu Natal, South Africa and in Kenya where
researchers in those countries also found similar asso-
ciation with HIV infection and severe malaria in chil-
dren [9,24,25]. In South Africa, the prevalence of HIV
among children with severe malaria was 17% compared
to 7.5% in children with uncomplicated malaria while
the study in Kenya, found a prevalence of 12% among
children admitted with severe malaria. In both studies,
the forms of severe malaria which the children pre-
sented with and HIV prevalence in cerebral malaria
were not reported.
The prevalence of HIV was lower than expected in
this study population probably because of early HIV
testing and diagnosis and initiation of cotrimoxazole
prophylaxis for children found to be HIV positive which
would also be protective against P. falciparum malaria
and severe forms of malaria [14,26,27]. None of the HIV
positive patients had been on prior cotrimoxazole pro-
phylaxis since their HIV status was unknown at the
time of enrolment.
HIV infected children in this study were more likely to
have hyperparasitaemia (parasite density >500,000/μl)
which was consistent with what was found in studies in
the Kenya y and Zimbabwe studies in which HIV infec-
tion was associated with higher parasite density [2,25].
Presumably, HIV infected children are less likely to
clear parasites from their blood than the non HIV
infected children because HIV infection impairs the
immune response to malaria parasites, leading to
decreased ability to control parasitaemia [2,5,28,29]. The
high parasitaemia places these children at a higher risk
of developing cerebral malaria because of the increased
likelihood of having the parasites sequester in the capil-
lary blood vessels. It is also possible that HIV-infected
children are at increased risk of developing cerebral
malaria because of an increased production of nitric
oxide synthase, ICAM-1 and VCAM-1 with HIV infec-
tion [30]. Nitric oxide has been suggested as a cause for
coma because of its ability to interfere with neurotrans-
mission in the brain [30,31]. However, other studies
have found no significant association with cerebral
malaria [32].
Due to the low number of HIV infected children in
our controls, we found no association between cerebral
malaria and low CD4 cell count. A longitudinal study in
Figure 1 Study profile.
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a. Characteristics of all children and their Cerebral malaria Uncomplicated malaria No malaria
care takers n = 100 n = 132 n = 120
Variable N (%) N (%) N (%)
Child factors
Age (Months)
≤59 81 (81) 90 (68.2) 76 (63.3)
>59 19 (19) 42 (31.8) 44 (36.7)
Sex M:F 01:00.7 01:00.7 01:00.7
Median duration of fever in days (IQR) 3 (2-4) 2 (1-4) -
Use of mosquito net
Yes 54 (54) 86 (65.2) 63 (52.5)
No 46 (46) 46 (34.8) 57 (47.5)
Immunization status
Fully/up-to-date 73 (73) 102 (77.3) 105 (87.5)
Partial/uncertain 27 (27) 30 (22.7) 15 (12.5)
Pre-hospital treatment
Yes 82 (82) 76 (57.6) -
No 18 (18) 56 (42.4)
Median parasite density (IQR) 23480 (1660-145960) 21680 (7350-54300)
HIV status
Positive 9 (9) 3 (2.3) 3 (2.5)
Negative 91 (91) 129 (97.7) 117 (97.5)
Caretaker factors
Age of caretaker (in years)
≤30 70 (70.0) 103 (78.0) 63 (52.5)
>30 30 (30.0) 29 (22.0) 57 (47.5)
Antimalarial medicines kept at home
Yes 28 (28) 36 (27.3) 25 (20.8)
No 72 (72) 96 (72.7) 95 (79.2)
Caretaker’s preferred first option
H/U 25 (25) 44 (33.3) 93 (77.5)
Other
2 75 (75) 88 (66.7) 27 (22.5)
Number of children <5y in the household
≤3 83 (83) 124 (93.9) 79 (84.9)
>3 17 (17) 8 (6.1) 14 (15.1)
b. Characteristics of cerebral malaria patients by HIV status HIV+ (n = 9) HIV- (n = 91) P-value
n (%) n = (%) OR (95% CI)
Age
≤59 Mo 7 (77.8) 74 (81.3)
>59 Mo 2 (22.2) 17 (18.7)
Duration of fever (days)
≤3 5 (55.6) 59 (35.2) 0.58
>3† 4 (44.4) 32 (64.8) 1.48 (0.27-7.37)
Median number of convulsions (IQR) 3 (2-3) 2 (1-5)
Pre-hospital treatment
Yes† 6 (66.7) 76 (83.5) <0.001
No 3 (33.3) 15 (16.5) 3.36 (1.81-6.21)
Median parasite density (IQR) 240,000 (3080-583520) 21,440 (1600-133080)
Parasite density/μl
>500,000† 2 (22.2) 2 (2.19) 0.003
≤500,000 7 (77.8) 89 (97.8) 12.71 (1.56-104.41)
n = number of children, IQR = Inter-quartile range,
1skilled laborers,
2tepid sponging/self-medication/herbs, H/U = health unit, † reference group.
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were associated with higher incidences of pneumonia,
sepsis, and tuberculosis but not of malaria( [33].
Other factors found to be associated with an increased
risk of presenting with clinical cerebral malaria were age
below five years and not using a mosquito net. These
findings are also consistent with previous studies
[16,34,35].
Our findings support the hypothesis that HIV infec-
tion is a risk factor for cerebral malaria in children. The
findings from this study add to the existing knowledge
of interaction between HIV infection and P. falciparum
Table 2 Comparing cerebral malaria and no malaria groups
Variable Cerebral Malaria No Malaria Unadjusted p-value
n = 100 n = 120 p-value Adjusted OR (95%CI)
N (%) N (%) OR (95%CI)
Age (Months)
≤59† 81 (81) 76 (63.3) 0.004 0.004
>59 19 (19) 44 (36.7) 2.47 (1.27-4.88) 2.49 (1.30-4.75)¶
Use of mosquito net 54 (54) 63 (52.5) 0.825 0.968
Yes† 46 (46) 57 (47.5) 1.06 (0.62-1.81) 0.99 (0.57-1.71)‡
No
HIV status 9 (9) 3 (2.5) 0.035 0.037
Positive† 91 (91) 117 (97.5) 3.86 (0.99-14.91) 3.85 (0.98-15.07)‡
Negative
Caretaker’s preferred first option H/U
Yes 25 (25) 93 (77.5) <0.001 <0.001
No† 75 (75) 27 (22.5) 10.33 (4.96-21.52) 9.93 (4.77-20.68)‡
Number of children <5y/household 83 (83) 79 (84.9) 0.714
≤3 17 (17) 14 (15.1) 1.16 (0.53-2.51)
>3†
n = number of children, CI confidence interval, OR odds ratio, H/U = health facility, † reference group, ¶ adjusted for HIV, ‡adjusted for age, CM = cerebral
malaria, NM = no malaria.
Table 3 Comparing cerebral malaria and uncomplicated malaria
Cerebral Malaria Uncomplicated Malaria Unadjusted
Variable n = 100 n = 132 p-value p-value
N (%) N (%) OR (95%CI) adjusted OR (95% CI)
Age (Months)
≤59† 81 (81) 90 (68.2) 0.028 0.016
>59 19 (19) 42 (31.8) 1.99 (1.07-3.69) 2.41 (1.14-4.02)‡
Use of mosquito net
Yes† 54 (54) 86 (65.2) 0.086 0.051
No 46 (46) 46 (34.8) 0.63 (0.37-1.07) 0.58 (0.34-1.01)¶
Pre-hospital treatment
Yes† 82 (82) 76 (57.6) <0.001 0.002
No 18 (18) 56 (42.4) 3.36 (1.81-6.21) 3.02 (1.52-5.99)¶
Median parasite density/μl
>500,000† 4 (4) 1 (0.76) 0.092 0.069
≤500,000 96 (96) 131 (99.24) 5.46 (0.53-270.77) 5.23 (0.71-38.59)¶
HIV status
Positive† 9 (9) 3 (2.3) 0.022 0.012
Negative 91 (91) 129 (97.7) 4.25 (1.10-16.44) 5.94 (1.23-28.72) ¶
Number of children <5y/household
≤3 83 (83) 124 (93.9) 0.008 0.005
>3† 17 (17) 8 (6.1) 3.18 (1.31-7.69) 4.03 (1.51-10.76)¶
CI = confidence interval, OR odds ratio, ‡ adjusted for HIV status, ¶ age-adjusted OR, † reference group, CM = cerebral malaria, UM = uncomplicated malaria.
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health importance.
Conclusions
HIV-1 infection is associated with clinical presentation
of cerebral malaria in children. Clinicians should ensure
that children diagnosed with HIV infection are initiated
on cotrimoxazole prophylaxis as soon as the diagnosis is
made and caretakers counselled on the importance of
adherence to the cotrimoxazole towards reducing the
risk of acquiring P. falciparum malaria and associated
complications such as cerebral malaria. Other malaria
preventive measures such as use of insecticide-treated
mosquito nets should also be emphasized during coun-
selling sessions.
Study Limitations
There are sources of potential sources of bias that can-
not be eliminated in this study. These inherent sources
include selection of no malaria controls from a hospital
setting which may have affected our results. We how-
ever tried to limit this by selecting hospital controls
from similar communities. We also excluded children
with conditions clearly documented to be associated
with HIV such as pneumonia, severe malnutrition, per-
sistent diarrhoea, and chronic otitis media. The design
of the study may have also affected the results. The case
control design may have led to exaggeration of the risk
because cases and controls were not matched on charac-
teristics such as age, maternal characteristics and others.
T h ep a r a s i t ed e n s i t ym a yn o tb eat r u er e f l e c t i o no ft h e
level of parasitaemia since the individual WBC count
was not available to estimate the parasite density but
instead assumed 8,000/μl. There is a possibility that the
WBC count was different in HIV+ and HIV- children.
Children with cerebral malaria were not followed up
to determine whether the outcome depended on HIV
serostatus. The strength of the study is that there were
more than one control groups and given that cerebral
malaria is a relatively rare complication of malaria,
it was an appropriate study design to conduct given
the time.
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